Manufacturing CBE 30s took six months for FDA to review
This article was originally published in The Gold Sheet
After six months, FDA Jan. 29 approved a "Changes Being Effected in 30 days" supplement that the agency had received July 29, 2008, from Valeant Pharmaceuticals International, Aliso Viejo, Calif., for an alternate repackaging site for its Mysoline (primidone) 50 mg tablets…. The agency took six months to review another CBE 30, this one from Bracco Diagnostics, Princeton, N.J. The approval came Nov. 26, 2008, for an application FDA had received May 27, 2008, for an alternate manufacturing site for its Technetium Tc 99m Medronate preparation kit
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.